frequency of false positive scans (26%), thus requiring further diagnostic workup. Age alone is not a reliable clinical variable because both congenital cervical cysts and metastatic disease show considerable overlap in their presentation along the age spectrum. However, a tendency for
immunodeficiency virus (HIV) infection (3, 4). Two prophylactic vaccines (Gardasil and Cervarix) have been approved for a decade. Recently, the nonavalent vaccine including additional high-risk HPV types is promised to provide more coverage against cervical cancers (5). The HPV vaccine is recommended routinely for 11- or 12-year-olds, as well as for young men through age 21 years and young women through age 26 years who have not previously been vaccinated. HPV vaccine is also recommended for men who
immunodeficiency virus (HIV) infection (3, 4). Two prophylactic vaccines (Gardasil and Cervarix) have been approved for a decade. Recently, the nonavalent vaccine including additional high-risk HPV types is promised to provide more coverage against cervical cancers (5). The HPV vaccine is recommended
Specific Aims Although the worldwide incidence of Head and Neck Squamous cell carcinoma (HNSCC) has been steadily declining over the past 20 years, it is still the sixth most common cancer by incidence with about 50% of mortality. Traditionally, the most notable risk factors for HNSCC are alcohol consumption and various forms of tobacco use, the combination of the two having a significantly synergistic effect on carcinogenesis. More recently, human papillomavirus (HPV)-associated oropharyngeal cancers